Briefcase

Identifying Patients at Risk of CKD in Pharmacy Settings

Launch Date
11/05/2021
Credit Amount
0.00 Expired
Credit Expires
11/05/2022
This activity is part of a series

Faculty

Dhiren K. Patel, PharmD, CDCES, BC-ADM
Adjunct Associate Professor of Pharmacy Practice
School of Pharmacy at Massachusetts College of Pharmacy and Health Sciences, Clinical Pharmacy Specialist, Boston, MA
Dhiren K. Patel, PharmD, CDCES, BC-ADM

Dhiren K. Patel, PharmD, CDCES, BC-ADM, is an adjunct associate professor of pharmacy practice in the School of Pharmacy at Massachusetts College of Pharmacy in Boston, MA. Dr. Patel maintained a clinical practice site at the Veterans Administration Boston Healthcare System for 12 years, where he functioned as an endocrine clinical pharmacy specialist in the Endocrine Department. He has recently transitioned to a Cardiometabolic Concierge Clinic. Dr. Patel currently serves on the Association of Diabetes Care & Education Specialists’ Technology Committee, American Diabetes Association’s Overcoming Therapeutic Inertia Initiative, and Centers for Disease Control and Prevention’s Diabetes Prevention Serious Game Steering Committee, and is a featured diabetes technology expert for the American Medical Association. Dr. Patel has also published in numerous peer-reviewed journals and delivered numerous presentations and lectures on diabetes and diabetes technology.

Diana Isaacs, PharmD, BCPS, BC-ADM, BCACP, CDCES, FADCES, FCCP
Endocrine Clinical Pharmacy Specialist
CGM and Remote Monitoring Program Coordinator
Co-Director Center of Excellence for Endocrine Disorders in Pregnancy, Cleveland Clinic Endocrinology & Metabolism Institute, Cleveland, OH
Diana Isaacs, PharmD, BCPS, BC-ADM, BCACP, CDCES, FADCES, FCCP

Diana Isaacs, PharmD, BCPS, BC-ADM, BCACP, CDCES, FADCES, FCCP, is the Remote Monitoring and Continuous Glucose Monitoring Program Coordinator and Endocrinology Clinical Pharmacy Specialist at the Cleveland Clinic Diabetes Center. Dr. Isaacs earned her bachelor?s degree in Chemistry from the University of Illinois at Chicago, Doctor of Pharmacy Degree from Southern Illinois University Edwardsville, and completed residency at the Philadelphia VA Medical Center. Dr. Isaacs holds board certifications in pharmacotherapy, ambulatory care, and advanced diabetes management. In 2020, she was awarded Fellow status in the Association of Diabetes Care and Education Specialists (ADCES) and American College of Clinical Pharmacy. She is the Communications Director for the American Diabetes Association (ADA) Pregnancy and Reproductive Health Interest Group, and serves on the 2020-2021 ADA Professional Practice Committee, the committee that updates the ADA Standards of Care. She is also the president of the Ohio ADCES. She presents on diabetes-related topics nationally and internationally. Dr. Isaacs was awarded the Ohio Pharmacists Association Under 40 Award in 2019 and ADCES Diabetes Care and Education Specialist of the Year in 2020.

Explore By Section
Statement of Need Learning Objectives Financial Support Target Audience Credit Information Disclosure Declaration Obtaining Credits

Statement of Need

Type 2 diabetes mellitus (T2DM) affects an estimated 29 million Americans and 463 million people worldwide, with that number projected to increase to 700 million by 2045. As approximately 40% of patients with T2DM develop chronic kidney disease (CKD), this has led to CKD being one of the most common diabetes complications, exposing patients to a 3-fold risk of cardiovascular death compared to those with T2DM alone. Also, most patients do not know that they have CKD until it is in an advanced stage. At minimal, yearly screening for eGFR and UACR in all patients with T2DM is recommended by the major kidney and diabetes guidelines to detect decline in the function of and damage to the kidneys; however, many patients do not receive these important screenings, resulting in delayed diagnosis and poorer outcomes for these unrecognized patients. The heavy burden of diabetes-associated CVD has become more widely acknowledged in recent years, leading to a shift in the T2DM management guidelines that includes a focus on early diagnosis and management of CKD in patients with T2DM.

The first episode of this CMEO BriefCase series on halting drivers of CKD progression will present a case study that will show when a patient with T2DM should undergo guideline-recommended screening with urine albumin excretion (UACR) and estimated glomerular filtration rate (eGFR) for early diagnosis of CKD.

Learning Objectives

At the end of this CME/CE activity, participants should be able to recognize when a patient should undergo guideline-recommended screening with UACR and eGFR for early diagnosis of CKD in patients with T2DM.

Financial Support

Supported by an educational grant from Bayer Healthcare Pharmaceuticals Inc.

Target Audience

Pharmacists

Credit Information

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Pharmacists/Pharmacy Tech (ACPE) 0.5

This application-based activity is approved for 0.5 contact hours (0.05 CEUs) of continuing pharmacy credit.
Activity UAN: JA0007185-0000-21-084-H04-P

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Patel reports that he is on the speakers bureau for Abbott; Amarin Corporation; AstraZeneca; Bayer; Boehringer Ingelheim; Dexcom, Inc.; Lilly; Novo Nordisk; Xeris Pharmaceuticals, Inc.; and Zealand Pharma.

Dr. Isaacs reports that she is on the speakers bureau for Abbot; Bayer Healthcare; Dexcom, Inc; Insulet Corporation; Medtronic; and Novo Nordisk. She reports that she is a consultant for DiabetesWise; The diaTribe Foundation; Tempramed; and Undermyfork.

Disclosures were obtained from the CME Outfitters, LLC, staff; no disclosures to report:

  • Mae Ochoa, RPh (peer reviewer)
  • Julie Strickland, PharmD (planning committee)
  • Heather Lewin, MAT (planning committee)
  • Kathleen Blake, PhD (planning committee)
  • Jan Perez (planning committee)
  • Sharon Tordoff (planning committee)

CME Outfitters, LLC, and the faculty do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

Obtaining Credits

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit https://www.cmeoutfitters.com/privacy-and-confidentiality-policy.

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).

BC-058-110521-61

Activities in the Series

Pharmacist Central
11/05/2021

Identifying Patients at Risk of CKD in Pharmacy Settings

0.00 Expired
Begin Learn More
Identifying Patients at Risk of CKD in Pharmacy Settings
Event Date: 11/05/2021
Begin